STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Mazdutide

Also known as

IBI362 · IBI-362 · LY3305677 · LY-3305677 · OXM3 (development / oxyntomodulin-analog discussions) · Xinermei · 信诺美 (China brand name) · GLP-1/glucagon dual agonist · GCG/GLP-1 dual agonist · mazdutide peptide · Mezdutide (common misspelling in dose lists)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic SubQ Metabolic / GLP-1 class

Systemic — a once-weekly GLP-1/glucagon dual agonist studied for appetite, weight, glucose and liver-metabolic effects.

What people say Mazdutide is a long-acting GLP-1/glucagon dual agonist given subcutaneously once weekly. It is approved in China for chronic weight management and type 2 diabetes, but not by the FDA or EU. Doses people talk about
Same-author community diary3 mg SC once weekly

The author reported early energy and appetite effects, then fatigue and nausea; at week two they reattributed much of the sickness to withdrawal after missing a prescription medication.

Phase 2 weekly targets3 / 4.5 / 6 mg SC once weekly

Randomized 24-week obesity trial after protocol-defined escalation; not a personal progression ladder.

GLORY-1 weekly targets4 / 6 mg SC once weekly

China Phase 3 maintenance targets after protocol-defined escalation.

GLORY-2 weekly target9 mg SC once weekly

China Phase 3 high-dose obesity target; the exact escalation is protocol-defined.

U.S. Phase 1 high-dose cohort16 mg SC once weekly

Small high-dose trial cohort used for the approximately 8-day half-life estimate; not an approved amount.

A separate Reddit poster wrote that mazdutide was being used with 'Tirz 5 mg'; the only explicit 5 mg amount belonged to tirzepatide and is not treated as a mazdutide dose.

Half-life & effect duration

Half-life in the body
  • Repeated-dose US studyAbout 8 days
  • First-dose Chinese studyAbout 7.3–44.8 days across small groups
Felt duration people report
  • One diary · energyWithin about 2 hours
  • Same diary · appetiteSuppression by the next day and through the week
  • Other early symptomsFatigue or nausea, partly reattributed to stopping another medicine
Timing context & sources
How it may feel A same-author 3 mg weekly diary reported energy within hours, appetite suppression by the next day, then fatigue, nausea and burping. At week two the author reattributed much of the early sickness to withdrawal from a missed prescription and still reported appetite suppression through the week.
Cycles people discuss Clinical studies use ongoing once-weekly therapy over months, with protocol-defined escalation rather than a short on/off cycle. No reviewed trial here establishes a self-directed hold, restart or missed-dose protocol. Timing Trials use once-weekly SC dosing with scheduled stepwise escalation, and GI events were most frequent during escalation before declining later. The reviewed studies do not establish self-directed dose holds, missed-dose handling or restart timing. Stacks Community posts discuss combining or switching among tirzepatide, semaglutide and retatrutide, but no reviewed human trial establishes concurrent mazdutide plus another incretin agonist. Watch for GI AEs (trial class): Diarrhea, nausea, vomiting, bloating, constipation, decreased appetite — most common; worse at higher doses and during titration.
Related
SemaglutideTirzepatideRetatrutideSurvodutideCagrilintide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The U.S. high-dose Phase 1 report measured an approximately 8-day half-life at 16 mg.

A separate Chinese Phase 1b first-dose analysis at 2.5 and 3 mg reported a much wider 7.3–44.8 day range and median Tmax around 72 hours.

Dose-, study- and sample-dependent early-phase estimates; the wide small-cohort range is not a universal personal half-life, and neither study validates gray-market material.

Felt duration people report

The diary described energy within about two hours, appetite suppression by the next day and through the week, with early fatigue and nausea later partly reattributed to prescription-medication withdrawal.

The author reported prior semaglutide and tirzepatide use, no concurrent drug at start, 3 mg weekly, and seven pounds down by week two.

Uncontrolled self-report with unverified product, prior incretin exposure, moving-related exertion and a missed prescription that materially changed adverse-effect attribution.

  • MESO-Rx forum — Same-author 3 mg mazdutide diary (opens in a new tab)Doodle's starting report as quoted in post #3261 and same-author updates in posts #3263, #3265–3267, #3270, #3272 and #3277: 3 mg at about 8 pm, energy around 9:45 pm, next-day appetite change, day-3 to week-1 fatigue/nausea, week-2 prescription-withdrawal reattribution, seven-pound change and persistent end-of-week suppression.Uncontrolled diary, unverified product, prior incretin exposure, missed prescription medication and moving-related exertion; amount is self-reported and not analytically confirmed.

Other context in this card

What people say 22

  • Phase 2 weight 24 weeks (Nature Comm 2023, ≤6 mg): Mean −6.7% (3 mg), −10.4% (4.5 mg), −11.3% (6 mg) vs +1.0% placebo; treatment differences vs placebo roughly −7.7% to −12.3%. trial
  • Phase 1b high dose (eClinicalMedicine 2022): ~9 mg titration arm ~11.7% mean weight loss at 12 weeks vs ~1.8% placebo; 10 mg cohort ~9.5% at 16 weeks vs ~3.3% placebo (different schedule/length — don’t merge as one curve). trial
  • GLORY-1 Phase 3 (NEJM 2025, n=610, 4 mg / 6 mg / placebo, 48 weeks): Treatment-policy week 48 mean % change −11.00% (4 mg), −14.01% (6 mg) vs +0.30% placebo. trial
  • GLORY-1 week 32 (primary window): −10.09% (4 mg), −12.55% (6 mg) vs +0.45% placebo; ≥5% responders ~74% / ~82% vs ~10.5% placebo. trial
  • GLORY-1 efficacy estimand (company tables): Week 48 ~−12.05% (4 mg) / ~−14.84% (6 mg) vs ~−0.47% placebo — note estimand differences when comparing headlines. trial
  • GLORY-1 ≥15% at week 48: ~35.7% (4 mg) / ~49.5% (6 mg) vs ~2.0% placebo (treatment-policy); efficacy estimand slightly higher. trial
  • GLORY-1 waist: Week 48 change ~−9.5 cm (4 mg) / ~−11.0 cm (6 mg) vs ~−1.5 cm placebo in reported secondary tables. trial
  • GLORY-2 Phase 3 (9 mg, 60 weeks): Mean weight reduction ~18.55% vs ~3.02% placebo; ~44% of mazdutide arm ≥20% loss vs ~2.6% placebo. trial
  • GLORY-2 non-T2D subgroup: Mean ~20.08% at week 60 vs ~2.81% placebo; ~48.7% hit ≥20% vs ~3.1% placebo — Innovent framed “>20% with a short 2-step titration” messaging. trial
  • GLORY-2 trajectory talk: Public toplines described continuous loss without plateau at week 60 — used in community “still dropping” comparisons to STEP-1-style plateaus (cross-trial, not head-to-head). trial
  • Phase 2 9 mg extended obesity arm (NCT04904913 high-dose part): ~18.6% placebo-adjusted mean % weight reduction at 48 weeks reported in company materials; ≥15% / ≥20% responder fractions ~51% / ~35% class figures in press tables. trial
  • Liver fat (Phase 2 obesity, LFC ≥5% by MRI-PDFF): Mazdutide 9 mg ~−73.3% relative liver-fat change at week 24; reduction described as sustained through 48-week extension. trial
  • DREAMS-1 Phase 3 T2D monotherapy (week 24, efficacy estimand): HbA1c −1.57% (4 mg) / −2.15% (6 mg) vs −0.14% placebo; HbA1c <7% in ~68.6% / ~87.4% vs ~10.7%; weight −5.61% / −7.81% vs −1.26%. trial
  • DREAMS-1 dual goal: HbA1c <7% and ≥5% weight loss ~40.6% (4 mg) / ~64.9% (6 mg) vs 0% placebo. trial
  • DREAMS-2 Phase 3 T2D add-on vs dulaglutide 1.5 mg (week 28): HbA1c −1.69% (4 mg) / −1.73% (6 mg) vs −1.38% dulaglutide; weight −7.31% / −9.24% vs −2.86%; dual HbA1c<7% + ≥5% loss ~50% / ~64% vs ~19%. trial
  • DREAMS-3 (T2D + obesity vs semaglutide): Head-to-head program; public coverage of superiority on combined glycemic + weight endpoints at mazdutide 6 mg vs sema 1 mg in some presentations — confirm exact dose/label context before treating as a universal “beats Ozempic” claim. trial
  • Cardiometabolic bundle: Trials report improvements in BP, lipids (notably triglycerides), uric acid, waist, and liver enzymes tracking weight loss. trial
  • Appetite: Decreased appetite is both an efficacy driver and a common AE table entry; community equates tolerated doses with “food noise” drop. trial
  • Dose-response: Across Phase 2 arms, higher weekly targets generally produced larger mean weight loss — drives 4 / 6 / 9 mg “step ladder” culture. trial
  • US / Lilly high-dose exploratory (Phase 1b-style up to 16 mg): Mean weight change near ~−20% to −21% at week 20 in small cohorts vs ~0% placebo in one published multiple-ascending-dose report — early, small-n, not a marketed regimen. trial
  • Phase 2 absolute loss framing (secondary coverage): ~6.4–9.9 kg class figures across 3 / 4.5 / 6 mg arms depending on source table — always pair with % change and baseline weight. trial
  • Meta-analysis framing (secondary literature): Pooled RCTs report mean weight and large triglyceride reductions vs placebo — useful class signal, still Chinese-trial–heavy. trial

Doses people talk about 15

  • Simplified community chart (preserved legacy context): The inherited profile records secondary peptide sites labeling 3, 6 and 9 mg weekly as ‘beginner,’ ‘moderate’ and ‘aggressive’ after four-week steps. No reviewed marketing source here corroborates that chart; separate reviewed programs studied 3, 4.5 and 6 mg targets and a 9 mg GLORY-2 target, which do not validate a generic 3→6→9 ladder. forum
  • Identity / potency risk: Research-vial mg ≠ clinical Innovent/Lilly material; COA claims are not guarantees of sterility, correct peptide, or labeled strength. forum
  • Combination evidence: No reviewed human trial established concurrent mazdutide use with semaglutide, tirzepatide, retatrutide or another incretin agonist. forum
  • Community trial-mimic ladder (preserved legacy context): The inherited profile records chart language of 1.5–3 mg weekly starts, ~4-week holds, a climb toward 6 mg then optional 9 mg, and some Western users starting at 1.5 mg even when blogs label 3 mg as ‘beginner.’ The reviewed MESO source itself documents only one 3 mg weekly diary whose author expected—but had not executed—a later move toward 9 mg. Neither is a recommendation. forum
  • Missed-dose discussion (preserved legacy context): The inherited profile records a forum class habit of taking a remembered dose when far from the next weekly day or skipping it when near the next dose. No reviewed mazdutide source here corroborates that rule, and the sponsor annual report is not the prescribing label. forum
  • Framing: Trial arms, China label context, and research-chem discussion only — not medical advice; not a U.S./EU label; not gray-market endorsement. forum
  • Frequency: Once-weekly subcutaneous — multi-day half-life supports weekly, not daily micro-dosing culture like some short peptides. trial
  • Injection sites: Abdomen, thigh, or upper arm SC; rotate sites; clinical trials used prefilled devices — gray market uses multi-use vials. trial
  • Phase 2 weekly maintenance targets (obesity, NCT04904913 low-dose part): 3 mg, 4.5 mg, 6 mg once weekly after stepwise escalation. trial
  • Phase 2 example titration (exact published schedules): 3 mg target: 1.5 mg weeks 1–4 → 3 mg weeks 5–24; 4.5 mg target: 1.5 → 3 (weeks 5–8) → 4.5 from week 9; 6 mg target: 2 mg weeks 1–4 → 4 mg weeks 5–8 → 6 mg from week 9. trial
  • GLORY-1 Phase 3: 4 mg and 6 mg once weekly after protocol titration (public coverage emphasizes these two maintenance doses for 32–48 weeks). trial
  • GLORY-2 / high-dose obesity: 9 mg once weekly maintenance; company materials stress a short 2-step titration to 9 mg (exact week-by-week kit schedule is protocol-defined — secondary blogs often simplify to 3→6→9 mg in ~4-week holds). trial
  • Phase 1b 9 / 10 mg exploration: 9 mg cohort escalated e.g. 3 → 6 → 9 mg over ~12 weeks; 10 mg cohort used longer multi-step climb (e.g. 2.5 → 5 → 7.5 → 10 mg over ~16 weeks) — different designs, different % loss timing. trial
  • T2D DREAMS bands: 4 mg and 6 mg once weekly dominate Phase 3 glycemic programs (monotherapy and add-on). trial
  • Exploratory high-dose PK (up to 16 mg weekly): Multi-step ladders such as 1.5/3/6/8/12/16 mg or 2/4/6/8/10/13/16 mg QW in small Phase 1b cohorts — research only, not community standard maintenance. trial

How it may feel 8

  • Weeks 8–16 (mid-ladder): GLORY-style 4–6 mg windows show solid mid-trial separation; many research logs debate holding 6 mg vs pushing toward 9 mg. forum
  • Days 1–7: First appetite drop and early fullness common; nausea/loose stools often appear after the first 1–2 injections as dual-receptor exposure starts. trial
  • Weeks 1–4 (titration start): Multi-step escalation begins (often 1.5–3 mg class starts in Phase 2, or 3 mg hold steps in community 3→6→9 charts); GI events cluster here and at each step-up. Visible scale change often modest until therapeutic dose is held. trial
  • Weeks 4–12: Mean weight pulls away from placebo in Phase 2 3–6 mg arms; appetite suppression typically strengthens if the weekly dose is held. trial
  • Months 3–6: 24-week Phase 2 / mid-Phase 3 anchors; double-digit mean % loss at higher arms when tolerated. trial
  • Months 6–12: GLORY-1 week 32–48 and Phase 2 9 mg 48-week data; waist, lipids, and liver-fat markers continue moving with loss. trial
  • Months 12–15 (GLORY-2 60-week window): 9 mg arm still separated from placebo with high ≥20% responder rates in non-T2D; “no plateau yet” messaging is trial-period language, not a guarantee for every user. trial
  • During trial escalation: Diarrhea, nausea and vomiting were more frequent during scheduled dose escalation and declined later in the 24-week study; this does not define a self-directed hold rule. trial

Cycles people discuss 7

  • Maintain vs stop: At goal weight, stay on a stable weekly dose vs stop — stop raises regain risk consistent with the whole incretin class. forum
  • Time off / restart (preserved legacy context): The inherited profile records inconsistent off-period practices and lower-step re-titration on restart. The reviewed 24-week trial did not test or establish a self-directed restart protocol. forum
  • Clinical model: Ongoing once-weekly chronic therapy for months (32–60+ week trial windows) — not a short on/off “blast.” trial
  • No studied “cycle off” for performance: GLORY/DREAMS did not define bodybuilding-style time-on/time-off; pauses in practice talk are for intolerability, pregnancy planning, supply, or medical workups — not a pharmacologic reset. trial
  • Trial escalation structure: GI events were most frequent during scheduled escalation and declined later; the published study did not test self-directed hold decisions. trial
  • Evidence windows to know: ~12 weeks (Phase 1b high dose), 24 weeks (Phase 2 low dose), 32/48 weeks (GLORY-1), ~48 weeks (Phase 2 9 mg / DREAMS windows), 60 weeks (GLORY-2) — these are study durations, not personal prescriptions. trial
  • Adolescent / other programs: Additional Phase 3 designs (adolescents, OSA, MASH/HFpEF exploration) exist in pipeline talk — not mature community dosing guides. trial

Timing 8

  • Washout after stop: Multi-day half-life implies multi-week declining exposure; appetite rebound timing varies. forum
  • Missed dose timing: Same weekly day preferred for steady levels; class forums allow flex within a few days if not near the next dose. forum
  • Half-life (high-dose Phase 1b): ~8 days reported at 16 mg weekly in one multiple-ascending-dose PK analysis — supports once-weekly SC. trial
  • Variability (Chinese Phase 1b): After the first 2.5 or 3 mg dose, reported terminal half-lives spanned 174.8–1075.7 hours (7.3–44.8 days) across very small cohorts. trial
  • Why weekly: Fatty-acid–modified oxyntomodulin-analog design extends exposure → once-weekly SC rather than multi-day native OXM. trial
  • Tmax (Chinese Phase 1b): Median peak exposure was about 72 hours after the first 2.5 or 3 mg dose, with an observed 12.1–170.2 hour range. trial
  • Titration vs PK: GI peaks track starts and dose steps more than a single peak-hour ritual; 4-week holds also let exposure approach steady state given multi-day half-life. trial
  • Downstream change: Weight, glucose, waist, liver fat, lipids move over weeks–months, not one injection. trial

More on what it is 8

  • Not the same as: Not tirzepatide (GIP/GLP-1 dual), not retatrutide (GIP/GLP-1/glucagon triple), not survodutide/pemvidutide/cotadutide (other dual programs), not daily short native OXM. forum
  • Access honesty: Outside China, public supply talk is gray-market research vials — not Xinermei pens, not trial kits, identity/potency unverified. forum
  • Community volume: Mid-tier vs sema/tirz/reta hype; Western logs still sparse and mostly copy trial titration rather than invent independent protocols. forum
  • What it is: Once-weekly dual GLP-1/glucagon peptide — Innovent IBI362 / Lilly LY3305677; mammalian oxyntomodulin (OXM) analog with fatty-acid extension for weekly SC use. China brand Xinermei (信诺美). trial
  • Why people search it: China Phase 2/3 (GLORY + DREAMS) showed double-digit % weight loss and strong glycemic data; NMPA approved both weight management and T2D in 2025 — first approved GCG/GLP-1 dual in that market. trial
  • Mechanism (plain): GLP-1 arm = satiety, slower gastric emptying, glucose-dependent insulin; glucagon arm framed as energy expenditure / hepatic fat oxidation on top of intake cut. trial
  • Evidence base: Phase 1b PK, multiple Chinese GLORY/DREAMS RCTs, and a now-published U.S. Phase 2 obesity RCT; China still supplies most pivotal experience, so cross-population comparison remains limited. trial
  • Regulatory: China NMPA approved mazdutide for chronic weight management in June 2025 and T2D in September 2025; it is not FDA/EU approved, and a U.S. Phase 2 obesity trial is now published. trial

Stacks 8

  • Primary “stack” is lifestyle: Resistance training + higher protein when large loss is expected — lean-mass protection is the real community stack, not another incretin. forum
  • Don’t dual-incretin: Almost never stacked with semaglutide, tirzepatide, retatrutide, survodutide, or other GLP-1/glucagon duals — redundant receptors, additive GI, zero combination RCT safety. forum
  • Sequencing > concurrent: More “switch agents” talk (sema → tirz → dual/triple → mazdutide interest) than true concurrent stacks; washout and re-titration discussed when switching. forum
  • GH-axis (minority): Occasional CJC/Ipamorelin, tesamorelin, or MK-677 co-talk for muscle/sleep while dieting — attribution for fat loss is confounded; not trial-supported with mazdutide. forum
  • Healing peptides (minority): BPC-157 / TB-500 / GHK-Cu sometimes appear in general peptide logs alongside GLP-1s for joints/skin — separate goals, not synergistic obesity data. forum
  • GI supports (practical): Electrolytes, fiber titration, smaller/lower-fat meals, anti-nausea strategies (ondansetron where prescribed, ginger, etc.) beat exotic peptide add-ons during escalation. forum
  • Oral med timing: Slowed gastric emptying can delay oral drug absorption (levothyroxine, warfarin INR monitoring talk in class guides). forum
  • Glucose-drug caution: If on insulin or sulfonylureas, clinical framing requires proactive glucose-drug adjustment — hypoglycemia risk rises with potent incretins (DREAMS context). trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 18

  • Gallbladder / biliary: Class discussion for rapid weight-loss incretins — watch right-upper-quadrant symptoms. forum
  • Injection site: Local redness, induration, bruising possible; rotate sites. forum
  • Lean mass / under-eating: Big appetite cut can trash protein and training recovery without deliberate nutrition — scale loss ≠ pure fat. forum
  • Source quality: Gray-market contamination, mislabel, under/over-filled mg, endotoxin — separate hazard from Innovent trial safety tables. forum
  • Regulatory / access: China NMPA approval ≠ FDA/EU approval or safe self-experimentation; research vials are not “the approved Chinese pen in a baggie.” forum
  • Not risk-free: Dual agonism still carries class GI burden, rare serious class risks, and long-term unknowns outside studied groups and durations. forum
  • GI AEs (trial class): Diarrhea, nausea, vomiting, bloating, constipation, decreased appetite — most common; worse at higher doses and during titration. trial
  • Phase 2 low-dose AE rates (published tables): Diarrhea ~36%, decreased appetite ~29%, nausea ~23%, vomiting ~14% — mostly mild–moderate, often transient. trial
  • GLORY-1 tolerability: GI events most frequent; mostly mild/moderate during escalation; AE-related discontinuation low (~1.5% at 4 mg, ~0.5% at 6 mg, ~1.0% placebo in NEJM report). trial
  • GLORY-2 GI intensity at 9 mg: Vomiting ~53.1% vs ~1.3% placebo and nausea ~46.9% vs ~3.2% placebo in PubMed abstract figures — majority mild/moderate/transient per company safety language; AE discontinuation ~2.9% vs 0% placebo. trial
  • GLORY-1 GI incidence talk: Secondary digests cite GI AEs in roughly half or more of participants at 6 mg-class exposure — expect escalation to be the hard window. trial
  • Hypoglycemia: Mild–moderate events appear in some T2D tables; severe hypoglycemia not the dominant story in monotherapy obesity trials, but risk rises with insulin/sulfonylureas. trial
  • Heart rate: Mild mean resting HR increase (~+2.6 bpm class figures in GLORY-1 coverage); flag persistent symptomatic tachycardia. trial
  • Thyroid C-cell / MTC class warning: Rodent GLP-1 class signal; personal/family MTC or MEN2 are absolute exclusions in class labeling logic. No calcitonin signal above common thresholds was highlighted in GLORY safety summaries, but monitoring talk remains. trial
  • Gastroparesis / severe GI disease: Class exclusion talk; delayed gastric emptying can worsen existing motility disease. trial
  • Population limit: Pivotal Phase 3 obesity/T2D programs enrolled Chinese adults — non-Asian PK/efficacy/AE rates not established at the same depth. trial
  • Pancreatitis class risk: GLP-1-class caution — abdominal pain + lipase/amylase rise is a stop signal in clinical framing. trial
  • Pregnancy / breastfeeding: Contraindicated in clinical framing; pause and plan with clinicians before conception attempts. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →